Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
68.14
+0.77 (1.14%)
At close: Mar 9, 2026, 4:00 PM EDT
68.25
+0.11 (0.16%)
After-hours: Mar 9, 2026, 7:48 PM EDT
| Period Ending | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalties | 867.84M | 780.29M | 699.31M | 618.59M | 570.99M | 522.62M | 482.00M | 468.82M | |||||||||||||||||||||
| Royalties Growth | 51.99% | 49.30% | 45.09% | 31.95% | 27.49% | 21.04% | 15.61% | 20.05% | |||||||||||||||||||||
| Product Sales | 376.44M | 333.14M | 325.57M | 322.95M | 303.49M | 303.73M | 303.64M | 298.64M | |||||||||||||||||||||
| Product Sales Growth | 24.04% | 9.68% | 7.22% | 8.14% | 0.88% | 7.55% | 18.02% | 30.02% | |||||||||||||||||||||
| Revenues Under Collaborative Agreements | 152.33M | 129.42M | 153.79M | 142.77M | 140.84M | 121.00M | 87.67M | 95.53M | |||||||||||||||||||||
| Revenues Under Collaborative Agreements Growth | 8.16% | 6.96% | 75.42% | 49.45% | 74.88% | 81.95% | -11.86% | 12.67% |
Operating Expense Breakdown
| Period Ending | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of Sales | 228.77M | 192.06M | 186.24M | 179.49M | 159.42M | 169.66M | 175.06M | 185.52M | |||||||||||||||||||||
| Cost of Sales Growth | 43.51% | 13.20% | 6.39% | -3.25% | -17.13% | -6.87% | 0.22% | 17.01% | |||||||||||||||||||||
| Selling, General, and Administrative | 207.09M | 172.31M | 167.47M | 161.56M | 154.34M | 149.69M | 143.72M | 146.96M | |||||||||||||||||||||
| Selling, General, and Administrative Growth | 34.18% | 15.11% | 16.52% | 9.94% | 3.45% | 0.25% | -3.23% | -12.03% | |||||||||||||||||||||
| Research and Development | 81.49M | 70.03M | 71.24M | 74.74M | 79.05M | 79.94M | 78.81M | 77.50M | |||||||||||||||||||||
| Research and Development Growth | 3.09% | -12.40% | -9.60% | -3.56% | 3.52% | 3.03% | 2.38% | 6.55% | |||||||||||||||||||||
| Amortization | 76.66M | 71.05M | 71.05M | 71.05M | 71.05M | 71.05M | 73.63M | 73.70M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||
| Amortization Growth | 7.90% | -0.00% | -3.50% | -3.60% | -3.69% | 17.31% | 9.22% | 20.85% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.